Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP science news

Show

From To
No new infections during research on preventive HIV pill in Belgium

According to the latest figures from Sciensano, 890 new diagnoses were made in Belgium last year, mainly in gay men and people from sub-Saharan Africa. This is a decrease of 27% compared to the peak of 2012.

Published
27 November 2018
From
Institute of Tropical Medicine
HIV Seroconversion Despite PrEP Therapy

The tragedy of continued HIV transmission in the era of pre-exposure prophylaxis (PrEP) is explored in detail in a viewpoint article published in Clinical Infectious Diseases.1 The study evaluated a cohort of 14 young black men who have sex with men (MSM) in Atlanta, Georgia, who experienced HIV seroconversion despite administration of PrEP as part of the EleMENt Study.

Published
22 November 2018
From
Infectious Disease Advisor
Trying to prevent and diagnose HIV at the same time – a Catch-22?

The doctors were puzzled by the fact that it wasn’t quite HIV. If it became HIV they could treat it. If it didn’t become HIV and went away they could discharge him. But this just being short of HIV all the time confused them.

Published
11 November 2018
From
Daily Maverick
How to evaluate PrEP and vaccines: urgency for next generation compounds

Several presentations at R4P 2018 looked at the new challenges of evaluating efficacy of new PrEP and vaccine candidates.

Published
05 November 2018
From
HIV i-Base
PrEP Is Safe for Pregnant Women Who Want the HIV Prevention Drug, a New Study Finds

Pre-exposure prophylaxis, or PrEP, is safe for pregnant women to use, according to new research presented at the HIV Research for Prevention (HIVR4P2018) conference in Madrid, Spain.

Published
05 November 2018
From
The Body Pro
How substance use affects adherence to PrEP among gay and bisexual men

On average, club drug users were no more likely to miss a dose of PrEP than non-club drug users. However, club drug use (at the event level) increased the odds of missing a dose on the same day by 55 percent and the next day (e.g., a "carryover effect") by 60 percent. "This suggests that although club drug users appeared to have similar aggregate levels of adherence, their missed doses were specifically timed around instances of club drug use.

Published
24 October 2018
From
Medical Xpress
First U.S. Failure of Truvada as PrEP Is Reported at IDWeek

A poster presentation at IDWeek, a yearly conference held by the Infectious Diseases Society of America, revealed that a 21-year-old Latinx man has acquired HIV despite consistently high adherence to pre-exposure prophylaxis (PrEP). This new report is unique for several reasons, primarily because this is the first known HIV seroconversion with verified adherence to PrEP in the U.S.

Published
07 October 2018
From
The Body Pro
Making Clinical Trials of PrEP More Inclusive of Women, No Matter Their Pregnancy Status

Three new trials of HIV prevention drugs seek to answer directly a question that researchers inside and outside the field of HIV have explicitly avoided for years: How do drugs work -- and are they safe -- in pregnant and breastfeeding women?

Published
01 October 2018
From
The Body Pro
← First1Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.